John Leonard
John Leonard, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20110030294 | Interior pane units and window with interior pane - Window with an interior pane; and an interior pane system having a frame unit, a pane unit connected to the unit, the pane unit having a pane, the frame unit applicable to a window, the window having an exterior pane, the window having a window opening, the frame unit sized and configured for positioning at the window opening; in some aspects, such a system including the window; and/or, in some aspects, such a system including a window cover connected to the frame. This abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure and is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims, 37 C.F.R. 1.72(b). | 02-10-2011 |
John Leonard, Macclesfield GB
Patent application number | Description | Published |
---|---|---|
20110015392 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 - A route for preparing a compound of formula (I) | 01-20-2011 |
20110319631 | PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS - Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ib-1: | 12-29-2011 |
20110319632 | PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS - Provided are compounds having Formula VIIIa-1: | 12-29-2011 |
20130245279 | PROCESSES FOR PREPARING BENZIMIDAZOLE COMPOUNDS - Provided are processes for the preparation of benzimidazole structures having Formula VIIIb-1: | 09-19-2013 |
John Leonard, Manchester GB
Patent application number | Description | Published |
---|---|---|
20100130748 | SNAR PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS - Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X | 05-27-2010 |
20100145065 | PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS - Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X | 06-10-2010 |
John Leonard, Auburn, NH US
Patent application number | Description | Published |
---|---|---|
20090263351 | Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases - Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease. | 10-22-2009 |
20120020916 | USE OF IL-12 AND IL-12 ANTAGONISTS IN THE TREATMENT OF AUTOIMMUNE DISEASES - Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease. | 01-26-2012 |
20130089515 | Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases - Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease. | 04-11-2013 |
John Leonard, Carlsbad, CA US
Patent application number | Description | Published |
---|---|---|
20090074760 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 03-19-2009 |
20110165159 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 07-07-2011 |
20130273041 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 10-17-2013 |
20140363424 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD | 12-11-2014 |
John Leonard, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20080280957 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof - Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds. | 11-13-2008 |
John Leonard, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20080242117 | APPARATUS TO REDUCE WAFER EDGE TEMPERATURE AND BREAKAGE OF WAFERS - In some embodiments radiation incident on a wafer is provided to perform an annealing process, and the wafer is cooled at an edge portion to reduce temperature and stress on the wafer. Other embodiments are described and claimed. | 10-02-2008 |
John Leonard, Mesa, AZ US
Patent application number | Description | Published |
---|---|---|
20110155129 | ENHANCED EDUCTOR DESIGN - The present invention provides for an enhanced eductor element that significantly increases the amount of pressure generated at the siphon tube without significantly increasing the flow resistance through the eductor. The invention further provides for breath-actuated inhalation devices comprising the enhanced eductor element as an actuation mechanism. | 06-30-2011 |
John Leonard, Dublin IE
Patent application number | Description | Published |
---|---|---|
20120011446 | GENERATING USER INTERFACES - An interface generator | 01-12-2012 |
John Leonard, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20120158500 | METHOD AND SYSTEM FOR MATCHING SELLERS WITH BUYERS - Methods, systems and computer readable medium are provided for matching providers with potential buyers. According to one method, custom proposed merchant offerings are established from merchant offerings data, stored in a database, based at least in part on at least one of a profile and transaction history of a first entity. The custom proposed merchant offerings are organized into a subset of proposed merchant offerings based, at least in part, on the transaction history of the first entity. The method further includes organizing the subset of proposed merchant offerings further based, at least in part, on geographic location to create an organized subset of proposed merchant offerings. The organized subset of proposed merchant offerings is presented to the first entity through a user interface. | 06-21-2012 |
20120215614 | SYSTEMS AND METHODS FOR AUTOMATICALLY PROVIDING RELEVANT OFFERS TO CUSTOMERS - Disclosed is a method including determining, by a computer based system for managing a rewards program, an assignment for transaction account data associated with a first transaction account. Thereafter, the first transaction account is assigned to a first population of a plurality of populations based on the transaction account data. Thereafter, an offer comprising an offer criteria is received from an offeror. Thereafter, the offer criteria is analyzed to identify a subset of the plurality of populations. The subset comprises the first population. Thereafter, the offer is communicated to the subset of the population. | 08-23-2012 |
20140046827 | SYSTEMS AND METHODS FOR FRAUD DETECTION USING A COOPERATIVE DATA EXCHANGE - A method is provided comprising receiving, at a first node, transactional data associated with a consumer (wherein the first node comprises a processor and a tangible, non-transitory memory), receiving, at the first node, a credit approval request associated with the consumer, wherein the credit approval request is associated with a proposed transaction, determining, by the first node, whether the transactional data conforms with the proposed transaction, and at least one of approving and denying the credit approval request in response to the determination. | 02-13-2014 |
John Leonard, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20150210681 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. | 07-30-2015 |